Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation.
Approaches to speed immune reconstitution following bone marrow transplantation (BMT) or peripheral-blood hematopoietic stem-cell transplantation (HSCT) could markedly reduce morbidity and mortality, particularly following partially major histocompatibility complex (MHC)-matched related donor (PMRD) transplants. However, it is critical to simultaneously eliminate the subpopulation of donor T cells that are alloreactive with the recipient and may produce graft-vs-host disease (GVHD). In this article, we discuss a number of promising cellular engineering approaches that could be applied to this problem, including the use of veto cells, regulatory T-cell subsets, and psoralen-treated donor lymphocytes. Emphasis is placed on whether these approaches can simultaneously transfer broad-spectrum immunity to the recipient without producing GVHD.
Jordan
Catherine T
CT
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322, USA.
Roback
John D
JD
D019264:Adoptive Transfer; D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003587:Cytomegalovirus / Q000276:immunology; D011564:Furocoumarins / Q000737:chemistry; D006086:Graft vs Host Disease / Q000276:immunology* / Q000517:prevention & control; D020350:Graft vs Tumor Effect / Q000276:immunology; D006801:Humans; D008285:Major Histocompatibility Complex / Q000276:immunology; D051379:Mice; D009894:Opportunistic Infections / Q000821:virology; D013601:T-Lymphocytes / Q000737:chemistry / Q000276:immunology* / Q000637:transplantation*; D014019:Tissue Donors; D014777:Virus Diseases / Q000276:immunology*
D011564:Furocoumarins; C118577:amotosalen